Recent efficacy and long-term survival of Astragalus polysaccharide combined with gemcitabine and S-1 in pancreatic cancer

doi:10.5306/wjco.v15.i11.1404

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (74)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-4)

Sum=63

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=10

Nov 24, 2024 (publication date) through Oct 15, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Nov 24, 2024; 15(11): 1404-1411
Published online Nov 24, 2024. doi: 10.5306/wjco.v15.i11.1404

Recent efficacy and long-term survival of Astragalus polysaccharide combined with gemcitabine and S-1 in pancreatic cancer

Guang-Yu Li, Jing Jiang

Guang-Yu Li, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310000, Zhejiang, China.

Guang-Yu Li, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China

Jing Jiang, Zhejiang Cancer Hospital, Hangzhou 310000, Zhejiang Province, China

Author contributions: Li GY contributed to data collection, analyzed the data, drafted the first draft; Jiang J conducted guidance and edited the manuscript; All authors have read and approved the final manuscript.

Institutional review board statement: This study was approved by the Ethics Committee of Zhejiang Provincial Hospital of Chinese Medicine (Ethics No. 2024-KLS-266-02).

Informed consent statement: With the approval of the Ethics Committee of Zhejiang Provincial Hospital of Chinese Medicine, informed consent is waived for this study.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Corresponding author: Jing Jiang, Professor, Zhejiang Cancer Hospital, Hangzhou 310000, Zhejiang Province, China. jjsgxhszlyy@gmail.com

Received: June 27, 2024
Revised: August 28, 2024
Accepted: September 12, 2024
Published online: November 24, 2024
Processing time: 108 Days and 22.4 Hours

Core Tip

Core Tip: Astragalus polysaccharide (APS) plays an active role in the treatment of malignant tumors based on traditional Chinese medicine (TCM). This study analyzed the effects of the combined therapy of APS and gemcitabine plus tegafur gimeracil oteracil potassium capsule (S-1) in the treatment of pancreatic cancer, showing improved objective response rate and disease control rate, increased CD4+ T cells and serum interleukin-2 levels, and prolonged median survival time. The findings demonstrated the potential of APS as an effective TCM-based treatment option in pancreatic cancer therapies.